All In Biotech

Drug Trial Radar · NCT04631107

AD109 Dose Finding in Mild to Moderate OSA

Phase 2 Randomized Double-Blind Placebo-Controlled 3-Period Single-Dose Crossover Study to Evaluate the Safety and Efficacy of Two Doses of AD-109 in Mild to Moderate Obstructive Sleep Apnea

Last checked: Nov 19, 2026Latest source record: Dec 22, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

32

Actual

Start

Dec 22, 2020

Primary completion

May 31, 2021

Study completion May 31, 2021

Sponsor

Lead sponsor
ApnimedIndustry
Sponsor type
Industry
First posted
Nov 17, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Crossover
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 25 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a randomized, 3-period, placebo-controlled, crossover, phase 2 clinical study to examine the efficacy and safety of 2 doses of AD109 vs placebo in patients with mild obstructive sleep apnea.

Conditions

  • Obstructive Sleep Apnea

Interventions

  • AD109 dose1- ADrug

    Oral administration at bedtime

  • AD109 dose2- BDrug

    Oral administration at bedtime

  • Placebo- CDrug

    Oral administration at bedtime

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in Hypoxic Burden (HB) Log Transformed - Log10HB[(%*Min)/h]Time frame: 1 night (8 hours)
  2. Change in Hypoxic Burden (HB) Raw Values - HB[(%*Min)/h]Time frame: 1 night (8 hours)

Locations

3 sites in 1 country. Site status is shown where the registry gives one.

  • Pacific Research Network

    San Diego, California

  • NeuroTrial Research

    Atlanta, Georgia

  • Brian Abaluck, LLC

    Philadelphia, Pennsylvania

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.